Division of Cell and Developmental Genetics, Department of Medicine, San Francisco VA Health Care System, San Francisco, CA, USA.
Institute for Human Genetics, University of California, San Francisco, CA, USA.
Cancer Sci. 2020 Aug;111(8):2987-2999. doi: 10.1111/cas.14506. Epub 2020 Jun 21.
Hepatocellular carcinoma (HCC) is a highly heterogeneous liver cancer with significant male biases in incidence, disease progression, and outcomes. Previous studies have suggested that genes on the Y chromosome could be expressed and exert various male-specific functions in the oncogenic processes. In particular, the RNA-binding motif on the Y chromosome (RBMY) gene is frequently activated in HCC and postulated to promote hepatic oncogenesis in patients and animal models. In the present study, immunohistochemical analyses of HCC specimens and data mining of The Cancer Genome Atlas (TCGA) database revealed that high-level RBMY expression is associated with poor prognosis and survival of the patients, suggesting that RBMY could possess oncogenic properties in HCC. To examine the immediate effect(s) of the RBMY overexpression in liver cancer cells, cell proliferation was analyzed on HuH-7 and HepG2 cells. The results unexpectedly showed that RBMY overexpression inhibited cell proliferation in both cell lines as its immediate effect, which led to vast cell death in HuH-7 cells. Transcriptome analysis showed that genes involved in various cell proliferative pathways, such as the RAS/RAF/MAP and PIP3/AKT signaling pathways, were downregulated by RBMY overexpression in HuH-7 cells. Furthermore, in vivo analyses in a mouse liver cancer model using hydrodynamic tail vein injection of constitutively active AKT and RAS oncogenes showed that RBMY abolished HCC development. These findings support the notion that Y-linked RBMY could serve dual tumor-suppressing and tumor-promoting functions, depending on the spatiotemporal and magnitude of its expression during oncogenic processes, thereby contributing to sexual dimorphisms in liver cancer.
肝细胞癌(HCC)是一种高度异质性的肝癌,在发病率、疾病进展和结局方面存在显著的男性偏向。先前的研究表明,Y 染色体上的基因可能在致癌过程中表达,并发挥各种男性特异性功能。特别是,Y 染色体上的 RNA 结合基序(RBMY)基因在 HCC 中经常被激活,并被推测在患者和动物模型中促进肝致癌作用。在本研究中,对 HCC 标本进行免疫组织化学分析,并对癌症基因组图谱(TCGA)数据库进行数据挖掘,结果表明高水平的 RBMY 表达与患者的预后和生存不良相关,表明 RBMY 可能在 HCC 中具有致癌特性。为了研究 RBMY 在肝癌细胞中的过表达对其直接影响,分析了 HuH-7 和 HepG2 细胞的细胞增殖。出乎意料的是,结果显示 RBMY 过表达在两种细胞系中均作为其直接效应抑制细胞增殖,导致 HuH-7 细胞大量死亡。转录组分析显示,RBMY 过表达在 HuH-7 细胞中下调了参与各种细胞增殖途径的基因,如 RAS/RAF/MAP 和 PIP3/AKT 信号通路。此外,在使用恒定性 AKT 和 RAS 癌基因经尾静脉水力注射的小鼠肝癌模型中的体内分析表明,RBMY 可消除 HCC 的发生。这些发现支持这样的观点,即 Y 连锁的 RBMY 可能根据其在致癌过程中的时空表达及其表达量,发挥双重肿瘤抑制和肿瘤促进作用,从而导致肝癌中的性别二态性。